Key facts
- This page summarizes Axel Bolte's Form 4 filing for Inozyme Pharma, Inc. (INZY).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Apr 2022, 16:05.
Axel Bolte - 19 Apr 2022 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- INZY
- Reported as of
- 19 Apr 2022
- Net transaction value
- +$249,998
- SEC form
- 4
- Accepted by SEC
- 20 Apr 2022, 16:05:37 UTC
- Prior SEC filing
- 28 Feb 2022
- Next SEC filing
- 13 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Axel Bolte
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Axel Bolte filed Form 4 for Inozyme Pharma, Inc. (INZY) on 20 Apr 2022.
Change
- Previous filing in this sequence was filed on 28 Feb 2022.
- Current net transaction value: +$249,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INZY
transaction
Common Stock
Purchase
- Transaction value
- $249,998
- Shares
- +67,750
- Change %
- +36%
- Price
- $3.69
- Shares after
- 258,575
- Date
- 19 Apr 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.